within Pharmacolibrary.Drugs.ATC.D;

model D10AD05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.9999999999999996e-06,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D10AD05</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Motretinide is a synthetic retinoid used primarily for dermatological conditions, particularly in the treatment of acne vulgaris. It is not widely used or commercially available today, and it is not approved in major pharmaceutical markets. Its application was similar to other topical retinoids.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data for motretinide exists in the biomedical literature as of 2024. Parameters below are estimated based on related retinoids used by a comparable topical route.</p><h4>References</h4><ol><li><p>Gollnick, H (1987). New indications and new retinoids. <i>Dermatologica</i> 175 Suppl 1 182–195. DOI:<a href=\"https://doi.org/10.1159/000248882\">10.1159/000248882</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3319725/\">https://pubmed.ncbi.nlm.nih.gov/3319725</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D10AD05;
